As a $677m evergreen fund, the proceeds from any exits will now be reinvested, Merck said.

Merck KGaA, a Germany-based healthcare and technology group, has increased its commitment to corporate venture capital with a further €600m ($677m) to invest over the next five years. As an evergreen fund, the proceeds from any exits will now be reinvested, Merck said. Merck’s CVC unit, M Ventures, had previously been allocated €400m and has…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.